Real-world treatment patterns and outcomes in ER+/PR+/HER2+metastatic breast cancer (MBC) patients: A National Cancer Database analysis.

被引：2

作者：

Statler, Abby

Nahleh, Zeina A.

Hobbs, Brian

Wei, Wei

Gupta, Annie

Blake, Cassann N.

机构：

[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[2] Cleveland Clin Florida, El Paso, TX USA

[3] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA

[4] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[5] Cleveland Clin Florida, Weston, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.1033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1033

引用

页数：2

共 50 条

[31] Real-world clinical outcomes and treatment patterns among metastatic breast cancer (MBC) patients with germline BRCA mutation (gBRCAmut).
Quek, Ruben
Mardekian, Jack
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2-breast cancer.
Landsman-Blumberg, Pamela
Namjoshi, Madhav
Thomson, Erin
Johnson, William
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] Treatment and outcomes of older versus younger women with HER2 positive metastatic breast cancer in the real-world national ESME database
Annonay, Mylene
Gauquelin, Lisa
Geiss, Romain
Ung, Mony
Cristol-Dalstein, Laurence
Mouret-Reynier, Marie-Ange
Goncalves, Anthony
Abadie-Lacourtoisie, Sophie
Francois, Eric
Perrin, Christophe
Le Fel, Johan
Lorgis, Veronique
Servent, Veronique
Uwer, Lionel
Jouannaud, Christelle
Leheurteur, Marianne
Joly, Florence
Campion, Loic
Courtinard, Coralie
Villacroux, Olivier
Petit, Thierry
Soubeyran, Pierre
Terret, Catherine
Bellera, Carine
Brain, Etienne
Delaloge, Suzette
BREAST, 2021, 60 : 138 - 146
[34] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
Chen, Tenghui
Zhang, Zhaojie
Gao, Lei
Scholz, Catherine
Gualberto, Antonio
Yu, Lihua
Yu, Kun
CANCER RESEARCH, 2022, 82 (12)
[35] A non-interventional study to characterize the real world treatment patterns and outcomes of women with ER+, HER2-advanced or metastatic breast cancer in Italy
De Laurentiis, M.
Mitra, D.
Bell, T.
Nuzzo, C. M. A.
De Placido, S.
CANCER RESEARCH, 2016, 76
[36] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
Olson, E. M.
Najita, J. S.
Sohl, J.
Arnaout, A.
Winer, E. P.
Lin, N. U.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] The mutational profile of ER-, PR+, HER2-metastatic breast cancer.
Fischbach, Neal A.
Huang, Richard S. P.
Lustberg, Maryam B.
Pelletier, Maureen
Pusztai, Lajos
Sivakumar, Smruthy
Sokol, Ethan
Ross, Jeffrey S.
Levy, Mia Alyce
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] Real-world characteristics, treatment patterns, and overall survival in patients with metastatic breast cancer (mBC) and CNS metastases
Alvarado-Miranda, A.
Cabrera-Galeana, P.
Munoz-Montano, W. R.
Lara-Medina, F.
Bargallo-Rocha, E.
Arrieta-Rodriguez, O.
Perez, M.
Porras-Reyes, F.
Mohar-Betancourt, A.
Gamboa, C.
CANCER RESEARCH, 2019, 79 (04)
[39] The role of adjuvant endocrine treatment in ER+, PR-, HER2-early breast cancer: a retrospective study of real-world data
Zhong, Miaochun
Ren, Xiaoqiu
Xia, Wenjie
Qian, Yangyang
Sun, Kewang
Wu, Jun
SCIENTIFIC REPORTS, 2024, 14 (01):
[40] First-line treatment patterns by age for patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry
Jahanzeb, M.
Tripathy, D.
Hurvitz, S. A.
O'Shaughnessy, J.
Mason, G.
Yardley, D. A.
Brufsky, A.
Rugo, H. S.
Cobleigh, M.
Swain, S. M.
Chu, L.
Antao, V.
Yoo, B.
Kaufman, P. A.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →